Should AIT in allergic rhinitis and/or asthma patients be
interrupted to reduce visits to health care centers during the COVID-19
pandemic?
Most AIT products authorized for use in Europe indicate that AIT should
be discontinued in case of infection; the same principle will apply to
the COVID-19 pandemic. Patients on subcutaneous or sublingual AIT, who
are diagnosed with COVID-19, those suspected of SARS-CoV-2 infection or
symptomatic patients with a positive contact to SARS-CoV-2 individuals,
AIT should be interrupted until the patient has recovered. In patients
not infected or who have recovered from the infection, AIT could be
continued (Table 3 ). These recommendations are conditional and
could change as clinical data evolve.108,118